Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017;12(4):313-319.
doi: 10.1080/17469899.2017.1319762. Epub 2017 Apr 26.

Comparative efficacy of steroid-sparing therapies for non-infectious uveitis

Jared E Knickelbein  1 , Meredith Kim  1 , Elvira Argon  1 , Robert B Nussenblatt  1 , Nida H Sen  1
Affiliations

Comparative efficacy of steroid-sparing therapies for non-infectious uveitis

Jared E Knickelbein et al. Expert Rev Ophthalmol. 2017.

Abstract

Introduction: Non-infectious uveitis encompasses a group of inflammatory eye diseases that can cause irreversible vision loss if left untreated or undertreated. In cases requiring stemic treatment, a step-wise treatment approach is often employed starting with corticosteroids for severe active disease, followed by initiation of steroid-sparing therapies to maintain inflammatory control and avoid the abundant complications of long-term corticosteroid use.

Areas covered: We review the current high-quality evidence comparing the efficacy of various systemic steroid-sparing agents in the treatment of non-infectious uveitis. For studies to be included, they had to have a prospective, randomized, comparative design or a retrospective design including at least 100 patients.

Expert commentary: Given the rarity of uveitis and the heterogeneity of uveitic diseases, there are few randomized controlled studies that directly compare the relative efficacy of the various steroid-sparing immunosuppressive agents. Therefore, current treatment strategies are based mainly on data from observational series.

Keywords: Non-infectious uveitis; adalimumab; azathioprine; cyclosporine; immunosuppression; infliximab; methotrexate; mofetil; mycophenolate.

PubMed Disclaimer

Conflict of interest statement

Declaration of interest The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending or royalties.

References

    1. Nussenblatt RB, Whitcup SM. Uveitis: Fundamentals and clinical practice(Mosby, Philadelphia, Pa, 2010).
    1. Woods AC. Clinical and experimental observation on the use of ACTH and cortisone in ocular inflammatory disease. Am J Ophthalmol, 33(9), 1325–1349 (1950). - PubMed
    1. Jabs DA, Rosenbaum JT, Foster CS et al. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol, 130(4), 492–513 (2000). - PubMed
    1. Nussenblatt RB, Palestine AG, Chan CC, Stevens G Jr, Mellow SD, Green SB. Randomized, double-masked study of cyclosporine compared to prednisolone in the treatment of endogenous uveitis. Am J Ophthalmol, 112(2), 138–146 (1991). - PubMed
    1. Denniston AK, Holland GN, Kidess A et al. Heterogeneity of primary outcome measures used in clinical trials of treatments for intermediate, posterior panuveitis. Orphanet journal of rare diseases,10, 97 (2015). - PMC - PubMed

LinkOut - more resources